A phase 1 study analyzing safety and immunogenicity of REC-601
Latest Information Update: 30 Aug 2022
At a glance
- Drugs REC 601 (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Jiangsu Recbio Technology
- 28 Aug 2022 Status changed from recruiting to completed, according to a Recbio media release.
- 28 Mar 2022 New trial record